Catalent (NYSE:CTLT) Reaches New 12-Month Low at $85.10

Catalent, Inc. (NYSE:CTLTGet Rating)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $85.10 and last traded at $86.63, with a volume of 8801 shares trading hands. The stock had previously closed at $87.15.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CTLT shares. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a report on Saturday, September 17th. Deutsche Bank Aktiengesellschaft decreased their price target on Catalent from $110.00 to $105.00 and set a “hold” rating on the stock in a research note on Tuesday, August 30th. Jefferies Financial Group decreased their price target on Catalent from $130.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, August 30th. Royal Bank of Canada decreased their price target on Catalent from $155.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 30th. Finally, Stephens decreased their target price on Catalent to $145.00 in a research note on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Catalent presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.13.

Catalent Trading Down 4.9 %

The business has a fifty day moving average price of $100.65 and a 200 day moving average price of $102.12. The firm has a market cap of $14.22 billion, a PE ratio of 27.94, a P/E/G ratio of 1.71 and a beta of 1.36. The company has a current ratio of 2.72, a quick ratio of 2.07 and a debt-to-equity ratio of 0.87.

Catalent (NYSE:CTLTGet Rating) last announced its earnings results on Monday, August 29th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.04. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.33 billion. Catalent had a return on equity of 14.49% and a net margin of 10.56%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $1.08 EPS. Analysts forecast that Catalent, Inc. will post 3.66 EPS for the current year.

Insider Buying and Selling

In other Catalent news, CEO Alessandro Maselli sold 816 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $87,230.40. Following the completion of the transaction, the chief executive officer now owns 25,083 shares of the company’s stock, valued at $2,681,372.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the sale, the chief executive officer now owns 25,083 shares of the company’s stock, valued at $2,681,372.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ricky Hopson sold 312 shares of Catalent stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $33,352.80. Following the completion of the sale, the insider now directly owns 17,035 shares of the company’s stock, valued at approximately $1,821,041.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,018 shares of company stock valued at $1,873,343. 0.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cerro Pacific Wealth Advisors LLC lifted its stake in shares of Catalent by 2.4% during the first quarter. Cerro Pacific Wealth Advisors LLC now owns 4,575 shares of the company’s stock worth $507,000 after purchasing an additional 107 shares in the last quarter. FDx Advisors Inc. lifted its stake in shares of Catalent by 1.9% in the second quarter. FDx Advisors Inc. now owns 5,712 shares of the company’s stock worth $613,000 after acquiring an additional 108 shares in the last quarter. Ellevest Inc. lifted its stake in shares of Catalent by 39.5% in the first quarter. Ellevest Inc. now owns 406 shares of the company’s stock worth $45,000 after acquiring an additional 115 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Catalent by 8.9% in the second quarter. Quadrant Capital Group LLC now owns 1,411 shares of the company’s stock worth $151,000 after acquiring an additional 115 shares in the last quarter. Finally, Cetera Advisor Networks LLC raised its stake in Catalent by 7.1% during the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after buying an additional 130 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.